|
1
|
Wagner AD and Wedding U: Advances in the
pharmacological treatment of gastro-oesophageal cancer. Drugs
Aging. 26:627–646. 2009.
|
|
2
|
Bittoni A, Maccaroni E, Scartozzi M,
Berardi R and Cascinu S: Chemotherapy for locally advanced and
metastatic gastric cancer: state of the art and future
perspectives. Eur Rev Med Pharmacol Sci. 14:309–314. 2010.
|
|
3
|
Catalano V, Labianca R, Beretta GD, Gatta
G, De Braud F, et al: Gastric cancer. Crit Rev Oncol Hematol.
71:127–164. 2009.
|
|
4
|
Moore MA, Eser S, Igisinov N, Igisinov S,
Mohagheghi MA, Mousavi-Jarrahi A, Ozentürk G, Soipova M, Tuncer M
and Sobue T: Cancer epidemiology and control in North-Western and
Central Asia - past, present and future. Asian Pac J Cancer Prev.
11:17–32. 2010.
|
|
5
|
Tsai JY and Safran H: Status of treatment
for advanced gastric carcinoma. Curr Oncol Rep. 5:210–218.
2003.
|
|
6
|
Murad AM, Santiago FF, Petroianu A, Rocha
PR, Rodrigues MA and Rausch M: Modified therapy with
5-fluorouracil, doxorubicin, and methotrexate in advanced gastric
cancer. Cancer. 72:37–41. 1993.
|
|
7
|
Pyrhönen S, Kuitunen T, Nyandoto P, et al:
Randomised comparison of fluorouracil, epidoxorubicin and
methotrexate (FEMTX) plus supportive care with supportive care
alone in patients with nonresectable gastric cancer. Br J Cancer.
71:587–591. 1995.
|
|
8
|
Glimelius B, Ekstrom K, Hoffman K, Graf W,
Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H
and Heuman R: Randomized comparison between chemotherapy plus best
supportive care with best supportive care in advanced gastric
cancer. Ann Oncol. 8:163–168. 1997.
|
|
9
|
Schipper DL and Wagener DJ: Chemotherapy
of gastric cancer. Anticancer Drugs. 7:137–149. 1996.
|
|
10
|
Cascinu S, Graziano F, Cardarelli N, et
al: Phase II study of paclitaxel in pretreated advanced gastric
cancer. Anticancer Drugs. 9:307–310. 1998.
|
|
11
|
Chao Y, Li CP, Chao TY, et al: An open,
multi-centre, phase II clinical trial to evaluate the efficacy and
safety of paclitaxel, UFT, and leucovorin in patients with advanced
gastric cancer. Br J Cancer. 95:159–163. 2006.
|
|
12
|
Einzig AI, Neuberg D, Remick SC, et al:
Phase II trial of docetaxel (Taxotere) in patients with
adenocarcinoma of the upper gastrointestinal tract previously
untreated with cytotoxic chemotherapy: the Eastern Cooperative
Oncology Group (ECOG) results of protocol E1293. Med Oncol.
13:87–93. 1996.
|
|
13
|
Sakamoto J, Morita S, Yumiba T, et al: A
phase II clinical trial to evaluate the effect of paclitaxel in
patients with ascites caused by advanced or recurrent gastric
carcinoma: a new concept of clinical benefit response for
nonmeasurable type of gastric cancer. Jpn J Clin Oncol. 33:238–240.
2003.
|
|
14
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al: Phase III study of docetaxel and cisplatin plus fluorouracil
compared with cisplatin and fluorouracil as first-line therapy for
advanced gastric cancer: a report of the V325 Study Group. J Clin
Oncol. 24:4991–4997. 2006.
|
|
15
|
Park SH, Lee WK, Chung M, et al:
Paclitaxel versus docetaxel for advanced gastric cancer: a
randomized phase II trial in combination with infusional
5-fluorouracil. Anticancer Drugs. 17:225–229. 2006.
|
|
16
|
Chon HJ, Rha SY, Im CK, Kim C, Hong MH,
Kim HR, An JR, Noh SH, Chung HC and Jeung HC: Docetaxel versus
paclitaxel combined with 5-FU and leucovorin in advanced gastric
cancer: combined analysis of two phase II trials. Cancer Res Treat.
41:196–204. 2009.
|
|
17
|
Ishikawa T, Sekiguchi F, Fukase Y, Sawada
N and Ishitsuka H: Positive correlation between the efficacy of
capecitabine and doxifluridine and the ratio of thymidine
phosphorylase to dihydropyrimidine dehydrogenase activities in
tumors in human cancer xenografts. Cancer Res. 58:685–690.
1998.
|
|
18
|
Ishikawa T, Utoh M, Sawada N, Nishida M,
Fukase Y, Sekiguchi F and Ishitsuka H: Tumor selective delivery of
5-fluorouracil by capecitabine, a new oral fluoropyrimidine
carbamate, in human cancer xenografts. Biochem Pharmacol.
55:1091–1097. 1998.
|
|
19
|
Cao S, Lu K, Ishitsuka H and Rustum YM:
Antitumor efficacy of capecitabine against fluorouracil-sensitive
and -resistant tumors. Proc Am Soc Clin Oncol. 16:266a1997.
|
|
20
|
Hong YS, Song SY, Lee SI, Chung HC, Choi
SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS and Cho JY: A phase II
trial of capecitabine in previously untreated patients with
advanced and/or metastatic gastric cancer. Ann Oncol. 15:1344–1347.
2004.
|
|
21
|
Kang YK, Kim TW, Chang HM, Ryu MH, Yook
JH, Oh ST, Kim BS and Lee JS: A phase I/II trial of docetaxel,
capecitabine, and cisplatin as a first line chemotherapy for
advanced gastric cancer. Proc Am Soc Clin Oncol. 22:40662004.
|
|
22
|
Park YH, Ryoo BY, Choi SJ and Kim HT: A
phase II study of capecitabine and docetaxel combination
chemotherapy in patients with advanced gastric cancer. Br J Cancer.
90:1329–1333. 2004.
|
|
23
|
Cho EK, Lee WK, Im SA, Lee SN, Park SH,
Bang SM, Park DK, Park YH, Shin DB and Lee JH: A phase II study of
epirubicin, cisplatin and capecitabine combination chemotherapy in
patients with metastatic or advanced gastric cancer. Oncology.
68:333–340. 2005.
|
|
24
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
|
|
25
|
Kang HJ, Chang HM, Kim TW, et al: A phase
II study of paclitaxel and capecitabine as a first-line combination
chemotherapy for advanced gastric cancer. Br J Cancer. 98:316–322.
2008.
|
|
26
|
Cunningham D, Starling N, Rao S, et al;
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom. Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008.
|
|
27
|
Webb A, Cunningham D, Scarffe JH, et al:
Randomized trial comparing epirubicin, cisplatin, and fluorouracil
versus fluorouracil, doxorubicin, and methotrexate in advanced
esophagogastric cancer. J Clin Oncol. 15:261–267. 1997.
|
|
28
|
Foukakis T, Lundell L, Gubanski M, et al:
Advances in the treatment of patients with gastric adenocarcinoma.
Acta Oncol. 46:277–285. 2007.
|
|
29
|
Sawada N, Ishikawa T, Fukase Y, et al:
Induction of thymidine phosphorylase activity and enhancement of
capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Clin Cancer Res. 4:1013–1019. 1998.
|
